Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

por Flanigan, Jaclyn, Deshpande, Hari, Gettinger, Scott
Publicado 2010

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer

por Deshpande, Hari A, Gettinger, Scott, Sosa, Julie Ann
Publicado 2010

Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

por Coleman, Emily, Panse, Gauri, Haldas, Jason, Gettinger, Scott N., Leventhal, Jonathan S.
Publicado 2018

Immuno-thermal ablations – boosting the anticancer immune response

por Slovak, Ryan, Ludwig, Johannes M., Gettinger, Scott N., Herbst, Roy S., Kim, Hyun S.
Publicado 2017

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

por Dhodapkar, Kavita M, Gettinger, Scott N, Das, Rituparna, Zebroski, Henry, Dhodapkar, Madhav V
Publicado 2013

Oncolytic virus immunotherapy: future prospects for oncology

por Raja, Junaid, Ludwig, Johannes M., Gettinger, Scott N., Schalper, Kurt A., Kim, Hyun S.
Publicado 2018

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

por Hughes, Jing, Vudattu, Nalini, Sznol, Mario, Gettinger, Scott, Kluger, Harriet, Lupsa, Beatrice, Herold, Kevan C.
Publicado 2015

Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy

por Adam, Lucas C., Raja, Junaid, Ludwig, Johannes M., Adeniran, Adebowale, Gettinger, Scott N., Kim, Hyun S.
Publicado 2018

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

por Dhodapkar, Kavita, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott, Kluger, Harriet, Dhodapkar, Madhav, Das, Rituparna
Publicado 2014

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

por Carvajal-Hausdorf, Daniel, Altan, Mehmet, Velcheti, Vamsidhar, Gettinger, Scott N., Herbst, Roy S., Rimm, David L., Schalper, Kurt A.
Publicado 2019

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

por Uhlig, Johannes, Case, Meaghan Dendy, Blasberg, Justin D., Boffa, Daniel J., Chiang, Anne, Gettinger, Scott N., Kim, Hyun S.
Publicado 2019

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

por Velcheti, Vamsidhar, Schalper, Kurt, Yao, Xiaopan, Cheng, Huan, Kocoglu, Mehmet, Dhodapkar, Kavita, Deng, Yanhong, Gettinger, Scott, Rimm, David L.
Publicado 2013

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

por Suozzi, Kathleen C., Stahl, Maximilian, Ko, Christine J., Chiang, Anne, Gettinger, Scott N., Siegel, Mark D., Bunick, Christopher G.
Publicado 2016

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1

por Kohrt, Holbrook, Kowanetz, Marcin, Gettinger, Scott, Powderly, John, Koeppen, Hartmut, Sosman, Jeffrey A, Cruz, Cristina, Xiao, Yuanyuan, Mokatrin, Ahmad, Fine, Gregg, Chen, Daniel S, Hodi, F Stephen
Publicado 2013

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

por Wakelee, Heather A., Gettinger, Scott, Engelman, Jeffrey, Jänne, Pasi A., West, Howard, Subramaniam, Deepa S., Leach, Joseph, Wax, Michael, Yaron, Yifah, Miles, Dale R., Lara, Primo N.
Publicado 2017

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

por Hellmann, Matthew D., Gettinger, Scott, Chow, Laura Q. M., Gordon, Michael, Awad, Mark M., Cha, Edward, Gong, Xiaohua, Zhou, Gongfu, Walker, Chris, Leopold, Lance, Heist, Rebecca S.
Publicado 2020

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

por Stamatouli, Angeliki M., Quandt, Zoe, Perdigoto, Ana Luisa, Clark, Pamela L., Kluger, Harriet, Weiss, Sarah A., Gettinger, Scott, Sznol, Mario, Young, Arabella, Rushakoff, Robert, Lee, James, Bluestone, Jeffrey A., Anderson, Mark, Herold, Kevan C.
Publicado 2018

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

por Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Publicado 2022

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

por Anagnostou, Valsamo K, Lowery, Frank J, Zolota, Vassiliki, Tzelepi, Vassiliki, Gopinath, Arun, Liceaga, Camil, Panagopoulos, Nikolaos, Frangia, Konstantina, Tanoue, Lynn, Boffa, Daniel, Gettinger, Scott, Detterbeck, Frank, Homer, Robert J, Dougenis, Dimitrios, Rimm, David L, Syrigos, Konstantinos N
Publicado 2010

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021